This could actually be the antidepressant competitors' attempt to take down AVNR as Nuedexta is infringing on their current locked market. The generics are simply creating noise to act like they really want to sell a generic form. Given that Nuedexta didn't even hit $100M in current run rate, why would they push so aggressively to want to get into this tiny market/? They are more concerned on AVNR's expansion of AVP-786 to indications like ALS, Alzheimer's, MS and DNS where they are probably more concerned about the loss of antidepressant sales and other drugs that are currently used to treat these indications.
It is the shorts who are funding both the generic anda suits and this lawsuit. Who has the most to loose, in the 100's of millions of dollars, the answer is the shorts. As the old saying goes follow the money- in this case it's the lost of money!